Viel-T Overview

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series A

  • Investors
  • 2

Viel-T General Information

Description

Developer of a ribonucleic acid therapeutic platform designed to treat viral infections and related diseases. The company utilizes gene-editing technology and non-coding RNA regulation to target specific genetic sequences, providing pharmaceutical firms with proprietary infection models and synthetic compound libraries intended to enable rapid response to emerging and mutant viruses.

Contact Information

Website
viel-t.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 204, Seongjang-dong, Jeonju Innovation Startup Hub
  • 67, Yusang-ro, Deokjin-gu
  • Jeonju, Jeonbuk 54852
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Discovery Tools (Healthcare)
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • Room 204, Seongjang-dong, Jeonju Innovation Startup Hub
  • 67, Yusang-ro, Deokjin-gu
  • Jeonju, Jeonbuk 54852
  • South Korea
+82

Viel-T Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Viel-T Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 01-Oct-2024 Completed Pre-Clinical Trials
2. Accelerator/Incubator 25-Jun-2024 Completed Pre-Clinical Trials
1. Seed Round 01-Apr-2024 Completed Pre-Clinical Trials
To view Viel-T’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Viel-T Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Viel-T Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Tech Incubator Program for Startup Accelerator/Incubator
Jeonbuk Technology Holdings Venture Capital Minority
To view Viel-T’s complete investors history, request access »

Ready to get started?

Request a free trial

Viel-T FAQs

  • Where is Viel-T headquartered?

    Viel-T is headquartered in Jeonju, South Korea.

  • What is the size of Viel-T?

    Viel-T has 9 total employees.

  • What industry is Viel-T in?

    Viel-T’s primary industry is Drug Discovery.

  • Is Viel-T a private or public company?

    Viel-T is a Private company.

  • What is Viel-T’s current revenue?

    The current revenue for Viel-T is .

  • How much funding has Viel-T raised over time?

    Viel-T has raised $1.23M.

  • Who are Viel-T’s investors?

    Tech Incubator Program for Startup and Jeonbuk Technology Holdings have invested in Viel-T.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process